Long-lasting response with lapatinib treatment: a case report

Risposta persistente in corso di trattamento con lapatinib: un caso clinico

Authors

  • Andrea Milani Divisione di Oncologia Clinica Investigativa (INCO), Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino (Italy)
  • Imperia Nuzzolese Divisione di Oncologia Medica-1, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino and Dipartimento di Oncologia, Università di Torino (Italy)
  • Giovanna Chilà Divisione di Oncologia Medica-1, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino and Dipartimento di Oncologia, Università di Torino, Torino (Italy)

DOI:

https://doi.org/10.19156/abtpn.2018.0030

Keywords:

Lapatinib, metastatic breast cancer, brain metastasis, HER2

Abstract

Lapatinib is a small molecule and a reversible inhibitor of HER2, which has shown to be effective on brain lesions in patients with HER2-positive breast cancer relapsed at the central nervous system (CNS). We report the clinical case of a young woman, treated with the combination of lapatinib and capecitabine from September 2009 to today for a metastatic recurrence of HER2-positive breast carcinoma at CNS level and who has achieved a complete response of the encephalic lesion and has not shown disease progression at systemic or CNS level, with excellent tolerance profile (Oncology).

Downloads

Download data is not yet available.